Check-Cap to merge with MBody AI in embodied AI workforce push
Labcorp Holdings Inc. (NYSE:LH) announced the results of its Annual Meeting held on May 15, 2025, where shareholders approved the 2025 Omnibus Incentive Plan and the 2025 Employee Stock Purchase Plan (ESPP). The company’s definitive proxy statement, filed with the SEC on April 4, 2025, contains detailed descriptions of both plans.
The 2025 Omnibus Incentive Plan aims to provide various stock-based compensation awards, including options, stock appreciation rights, restricted stock, restricted stock units, and other equity-based awards. The 2025 ESPP allows eligible employees to purchase common stock at a discount, thereby encouraging stock ownership among employees. InvestingPro data reveals management has been actively buying back shares, demonstrating alignment with shareholder interests. The stock has delivered impressive returns, with a 9.24% gain year-to-date.
During the Annual Meeting, shareholders also elected directors to the Board for terms expiring at the 2026 Annual Meeting, and ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, an advisory vote approved the compensation of the company’s named executive officers.
The shareholder meeting saw a quorum with 76,049,607 shares represented in person or by proxy out of the 83,668,573 shares issued and outstanding as of the record date, March 20, 2025.
The detailed voting results for the election of directors showed strong support for all nominees, with each receiving a significant majority of the votes cast. Similarly, the advisory vote on executive compensation and the ratification of the company’s independent auditor passed with substantial majorities.
The approval of the new incentive plans reflects shareholder support for Labcorp’s strategies to align the interests of its employees with those of its shareholders. The company’s commitment to good corporate governance practices and transparency is evidenced by the detailed reporting and filing of results with the SEC.
This information is based on the SEC 8-K filing by Labcorp Holdings Inc. and provides key insights into the company’s governance and compensation strategies moving forward.
In other recent news, LabCorp Holdings Inc reported its Q1 2025 earnings, showing a revenue increase of 5.3% year-over-year to $3.3 billion, though this fell short of the anticipated $3.41 billion. The company achieved an adjusted earnings per share (EPS) of $3.84, slightly surpassing the expected $3.78. LabCorp is targeting $100-$125 million in cost savings through its Launchpad initiative. The company also announced new product launches, including LabCorp Plasma Complete and genetic risk panel tests. LabCorp provided guidance for enterprise revenue growth between 6.7% and 8% for the year, with diagnostics revenue expected to grow by 6.5% to 7.7% and Biopharma Laboratory Services revenue by 3% to 5%. Adjusted EPS guidance for the year is set between $15.70 and $16.40. The company is also focusing on high-growth areas such as oncology and women’s health, maintaining a strong competitive position with strategic partnerships.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.